AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3886851 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group 4, 27 cases)
Number of subjects: 174
Study 29316931 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel multi-component fortifier and protein supplement derived from donkey milk
Number of subjects: 0
Study 29316931 — intervention group
Group type: COMPARATOR
Intervention: Control bovine milk-based multicomponent fortifier and protein supplement
Number of subjects: 0
Study 27434084 — intervention group
Group type: EXPERIMENTAL
Intervention: β-alanine supplementation (6.4 g·d for 28 days)
Number of subjects: 14
Study 27434084 — intervention group
Group type: EXPERIMENTAL
Intervention: β-alanine supplementation (1.2 g·d during 5 weeks of SIT)
Number of subjects: 14
Study 27434084 — intervention group
Group type: EXPERIMENTAL
Intervention: β-alanine supplementation
Number of subjects: 14
Study 27434084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 24447063 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day health education program
Number of subjects: 738
Study 23348419 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot objects
Number of subjects: 60
Study 23348419 — intervention group
Group type: COMPARATOR
Intervention: Cold objects
Number of subjects: 60
Study 21206546 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg (n = 8)
Number of subjects: 21
Study 21206546 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 21
Study 18818093 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially covered self-expandable metallic stent (SEMS)
Number of subjects: 62
Study 18818093 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare self-expandable metallic stent (SEMS)
Number of subjects: 62
Study 18818093 — intervention group
Group type: COMPARATOR
Intervention: External biliary drainage tube insertion
Number of subjects: 62
Study 16005229 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiestrogen therapy for 3 years after primary surgery and radiotherapy
Number of subjects: 97
Study 16005229 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 positivity
Number of subjects: 97
Study 16005229 — intervention group
Group type: EXPERIMENTAL
Intervention: High clinical stage and negative estrogen receptor status
Number of subjects: 97
Study 12929694 — intervention group
Group type: EXPERIMENTAL
Intervention: Root ZX
Number of subjects: 32
Study 12929694 — intervention group
Group type: COMPARATOR
Intervention: Endo Analyzer Model 8005
Number of subjects: 32
Study 10664481 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel orientation aiming task
Number of subjects: 0
Study 10664481 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpendicular orientation aiming task
Number of subjects: 0
Study 10664481 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear measures
Number of subjects: 0
Study 10664481 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural organization for upright standing and aiming
Number of subjects: 0
Study 10664481 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural variability
Number of subjects: 0
Study 8842657 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.4 mg kg‐1 i.v. (15 patients)
Number of subjects: 30
Study 8842657 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1 mg kg‐1 i.v. bolus, followed by continuous infusion (15 patients)
Number of subjects: 30
Study 8842657 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Midazolam and Propofol) after intubation
Number of subjects: 30
Study 1496708 — intervention group
Group type: EXPERIMENTAL
Intervention: Young coconut water
Number of subjects: 0
Study 6130295 — intervention group
Group type: EXPERIMENTAL
Intervention: Red-cell concentrate
Number of subjects: 0
Study 6130295 — intervention group
Group type: EXPERIMENTAL
Intervention: Red-cell suspension in SAGM medium
Number of subjects: 0
Study 6130295 — intervention group
Group type: COMPARATOR
Intervention: Whole blood
Number of subjects: 0
Study 6130295 — intervention group
Group type: EXPERIMENTAL
Intervention: Red cells
Number of subjects: 0
Study 31727361 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg combined with rosuvastatin 5 mg (R5 + E10)
Number of subjects: 408
Study 31727361 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg combined with Ezetimibe 10 mg (R10 + E10)
Number of subjects: 408
Study 28692728 — intervention group
Group type: EXPERIMENTAL
Intervention: BLISS intervention (baby-led approach to complementary feeding)
Number of subjects: 206
Study 28692728 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional spoon-feeding)
Number of subjects: 206
Study 28692728 — intervention group
Group type: EXPERIMENTAL
Intervention: BLISS intervention
Number of subjects: 206
Study 25847819 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy (3D-CRT)
Number of subjects: 763
Study 25847819 — intervention group
Group type: COMPARATOR
Intervention: Intensity-modulated radiation therapy (IMRT)
Number of subjects: 763
Study 24346989 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus chlorhexidine oral rinse at baseline and supportive periodontal therapy at 3 and 6 months
Number of subjects: 514
Study 24346989 — intervention group
Group type: COMPARATOR
Intervention: No treatment for 6 months
Number of subjects: 514
Study 21304215 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 60 mg (F60)
Number of subjects: 2
Study 21304215 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg combined with ezetimibe 10 mg (F20/E10)
Number of subjects: 2
Study 19258829 — intervention group
Group type: EXPERIMENTAL
Intervention: Presurgical exercise training
Number of subjects: 9
Study 16681770 — intervention group
Group type: EXPERIMENTAL
Intervention: Array-based comparative genomic hybridization (array CGH)
Number of subjects: 60
Study 16681770 — intervention group
Group type: EXPERIMENTAL
Intervention: TaqMan polymerase chain reaction
Number of subjects: 60
Study 14975458 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg daily
Number of subjects: 34
Study 14975458 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus nimesulide
Number of subjects: 34
Study 14975458 — intervention group
Group type: COMPARATOR
Intervention: Fradafiban (control group)
Number of subjects: 34
Study 14975458 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Aspirin, Nimesulide, Fradafiban)
Number of subjects: 34
Study 11564023 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquadry Clear Advantage sheath
Number of subjects: 58
Study 11564023 — intervention group
Group type: EXPERIMENTAL
Intervention: Incare sheath
Number of subjects: 58
Study 11564023 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheaths with applicator
Number of subjects: 58
Study 10345907 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education
Number of subjects: 408
Study 10345907 — intervention group
Group type: COMPARATOR
Intervention: Stress management (attention-placebo control)
Number of subjects: 408
Study 8071301 — intervention group
Group type: EXPERIMENTAL
Intervention: Open treatment with clinician's choice, including continued phenelzine and combination with amitriptyline
Number of subjects: 20
Study 8071301 — intervention group
Group type: EXPERIMENTAL
Intervention: Open treatment with clinician's choice, including a variety of other treatments
Number of subjects: 20
Study 3377948 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 1 mg
Number of subjects: 44
Study 3377948 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 2 mg
Number of subjects: 44
Study 3377948 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Number of subjects: 44
Study 3377948 — intervention group
Group type: COMPARATOR
Intervention: i.v. morphine 30 mg
Number of subjects: 44
Study 4877736 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust extract in a carbol saline solution
Number of subjects: 96
Study 4877736 — intervention group
Group type: COMPARATOR
Intervention: Carbol saline solution only (control)
Number of subjects: 96
Study 31714106 — intervention group
Group type: EXPERIMENTAL
Intervention: Judgments of friends' drinking status and maximum drinks per day
Number of subjects: 654
Study 31714106 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of contact with friends
Number of subjects: 654
Study 31714106 — intervention group
Group type: EXPERIMENTAL
Intervention: Friends' weekly consumption
Number of subjects: 654
Study 30737835 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel with prednisone (5 mg twice daily for 3 cycles)
Number of subjects: 18
Study 30737835 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel monotherapy
Number of subjects: 18
Study 30737835 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel with prednisone
Number of subjects: 18
Study 28549331 — intervention group
Group type: EXPERIMENTAL
Intervention: High Chances of Quitting (HCQ)
Number of subjects: 103
Study 28549331 — intervention group
Group type: COMPARATOR
Intervention: Average Chances of Quitting (ACQ)
Number of subjects: 103
Study 25735497 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 0.6 mg mixed with PCA (RPCA group)
Number of subjects: 0
Study 25735497 — intervention group
Group type: COMPARATOR
Intervention: Palonosetron 75 μg (P group)
Number of subjects: 0
Study 25735497 — intervention group
Group type: COMPARATOR
Intervention: Ramosetron 0.3 mg (R0.3 group)
Number of subjects: 0
Study 25735497 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (C group)
Number of subjects: 0
Study 23438090 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (web-assisted tobacco quality improvement intervention)
Number of subjects: 564
Study 23438090 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 564
Study 23438090 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 564
Study 23438090 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 564
Study 21705068 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet intervention (dietary consultation every 3 months with monthly nurse support)
Number of subjects: 593
Study 21705068 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus activity intervention (dietary consultation every 3 months with monthly nurse support plus a pedometer-based activity programme)
Number of subjects: 593
Study 21705068 — intervention group
Group type: COMPARATOR
Intervention: Usual care (initial dietary consultation and follow‐up every 6 months)
Number of subjects: 593
Study 21705068 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 593
Study 21705068 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet intervention and diet plus activity
Number of subjects: 593
Study 19324137 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia plus epidural (GAE)
Number of subjects: 74
Study 19324137 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia only (GA)
Number of subjects: 74
Study 16981967 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily urokinase (5000-6000 IU/kg/dose)
Number of subjects: 30
Study 16981967 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily urokinase (2500-3000 IU/kg/dose)
Number of subjects: 30
Study 15194094 — intervention group
Group type: EXPERIMENTAL
Intervention: All-polyethylene (AP) tibial component
Number of subjects: 21
Study 15194094 — intervention group
Group type: COMPARATOR
Intervention: Metal-backed (MB) tibial component
Number of subjects: 21
Study 10775722 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (2% lidocaine and 100 microg of fentanyl infused through lumbar epidural catheters)
Number of subjects: 108
Study 10775722 — intervention group
Group type: COMPARATOR
Intervention: No anesthesia (control group)
Number of subjects: 108
Study 10775722 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 108
Study 9286186 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (80 mg/day)
Number of subjects: 64
Study 9286186 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine (60 mg/day)
Number of subjects: 64
Study 9286186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 8139135 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human erythropoietin (rHuEPO) at doses of 3,000 and 6,000 IU, administered once per week for 8 weeks.
Number of subjects: 20
Study 8139135 — intervention group
Group type: COMPARATOR
Intervention: Intravenous recombinant human erythropoietin (rHuEPO) at doses of 3,000, 6,000, and 9,000 IU, administered once per week for 8 weeks.
Number of subjects: 20
Study 2949974 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg daily)
Number of subjects: 38
Study 2949974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 29105279 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency sphenopalatine ganglion stimulation
Number of subjects: 16
Study 29105279 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study 27590291 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg
Number of subjects: 0
Study 27590291 — intervention group
Group type: COMPARATOR
Intervention: SC IFN‐β‐1a 44 μg
Number of subjects: 0
Study 24943673 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial Programme for 12 weeks
Number of subjects: 1200
Study 24943673 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial Programme for 52 weeks
Number of subjects: 1200
Study 24943673 — intervention group
Group type: COMPARATOR
Intervention: Brief Intervention
Number of subjects: 1200
Study 22288770 — intervention group
Group type: EXPERIMENTAL
Intervention: Static magnetic field (SMF) exposure (0-192 mT peak-to-peak magnetic induction and 19 T/m lateral gradient at 3 mm from the magnets) for 5 minutes
Number of subjects: 79
Study 22288770 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 79
Study 20868461 — intervention group
Group type: EXPERIMENTAL
Intervention: Family‐Focused Treatment‐Health Promoting Intervention (FFT‐HPI)
Number of subjects: 46
Study 20868461 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 46
Study 20031665 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 635
Study 20031665 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 635
Study 17219034 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole at 15 mg per day
Number of subjects: 60
Study 17219034 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole at 2.1 mg per day
Number of subjects: 60
Study 17219034 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who experienced 'wearing-off'
Number of subjects: 60
Study 17219034 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not experience 'wearing-off'
Number of subjects: 60
Study 14709221 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with parameters: wavelength of 830 nm, power of 30 mW, frequency of 30 Hz, energy output of 1.1 J/cm2
Number of subjects: 20
Study 14709221 — intervention group
Group type: COMPARATOR
Intervention: Placebo LLLT
Number of subjects: 20
Study 14709221 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT
Number of subjects: 20
Study 11106918 — intervention group
Group type: EXPERIMENTAL
Intervention: octreotide LAR 20 mg once monthly for three months
Number of subjects: 125
Study 8842608 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia (blood glucose 15.7 +/‐ 0.48 mmol/l)
Number of subjects: 6
Study 8842608 — intervention group
Group type: COMPARATOR
Intervention: Euglycemia (blood glucose 5.1 +/‐ 0.04 mmol/l)
Number of subjects: 6
Study 8197926 — intervention group
Group type: EXPERIMENTAL
Intervention: Various statistical concepts related to trial design and analysis
Number of subjects: 0
Study 2981045 — intervention group
Group type: EXPERIMENTAL
Intervention: Human growth hormone (hGH) 7 IU subcutaneously daily for 2 months, followed by salmon calcitonin (CT), 100 MRC units every other day for 3 months, repeated twice after a 3 month rest period
Number of subjects: 14
Study 2981045 — intervention group
Group type: COMPARATOR
Intervention: Salmon calcitonin (CT) given intermittently in the same time periods and at the same dose as in the coherence treatment group
Number of subjects: 14
Study 31520149 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational group therapy module (STEM) with 8 sessions plus 3 sessions on stigma coping and empowerment
Number of subjects: 462
Study 31520149 — intervention group
Group type: COMPARATOR
Intervention: Standard psychoeducational group therapy extended to 11 sessions plus 1 booster session
Number of subjects: 462
Study 31520149 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational group therapy module (STEM)
Number of subjects: 462
Study 31520149 — intervention group
Group type: COMPARATOR
Intervention: Standard psychoeducational group therapy
Number of subjects: 462
Study 29478929 — intervention group
Group type: EXPERIMENTAL
Intervention: Persica (herbal mouthwash)
Number of subjects: 54
Study 29478929 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho-Kin (diluted chlorhexidine mouthwash)
Number of subjects: 54
Study 29478929 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 54
Study 29478929 — intervention group
Group type: EXPERIMENTAL
Intervention: Both mouthwashes (Persica and Ortho-Kin)
Number of subjects: 54
Study 27706464 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow conditioned oxygen therapy
Number of subjects: 604
Study 27706464 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 604
Study 25915102 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV
Number of subjects: 221
Study 25915102 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 221
Study 25915102 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification (control group)
Number of subjects: 221
Study 24314053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ego-depletion condition
Number of subjects: 130
Study 24314053 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 130
Study 21178076 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (400 mg daily)
Number of subjects: 174
Study 21178076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 18294405 — intervention group
Group type: EXPERIMENTAL
Intervention: Early part-time sick leave (work time reduced by 40-60%)
Number of subjects: 600
Study 18294405 — intervention group
Group type: COMPARATOR
Intervention: Conventional full-day sick leave (work load totally eliminated)
Number of subjects: 600
Study 16282531 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric inference procedures for Omega in the presence of dependent and independent censoring
Number of subjects: 0
Study 16282531 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric inference procedures for Omega in the presence of dependent interval censorship
Number of subjects: 0
Study 14583235 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hemisphere's hematoma
Number of subjects: 26
Study 14583235 — intervention group
Group type: COMPARATOR
Intervention: Right hemisphere's hematoma
Number of subjects: 26
Study 10890617 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornithine alpha-ketoglutarate
Number of subjects: 47
Study 10890617 — intervention group
Group type: COMPARATOR
Intervention: Protil-1 (isonitrogenous control)
Number of subjects: 47
Study 7602235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 7602235 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO 150 U/kg
Number of subjects: 71
Study 7602235 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO 300 U/kg
Number of subjects: 71
Study 7602235 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO 600 U/kg
Number of subjects: 71
Study 2403585 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotomy
Number of subjects: 53
Study 2403585 — intervention group
Group type: COMPARATOR
Intervention: No amniotomy
Number of subjects: 53
Study 580217 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐(m‐methoxyphenyl)‐2‐(dimethylaminomethyl)‐cyclohexan‐1‐ol (tramadol; Tramal) 100 mg i.m.
Number of subjects: 30
Study 580217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30091151 — intervention group
Group type: EXPERIMENTAL
Intervention: Client with current suicidal ideation and a history of attempts
Number of subjects: 86
Study 30091151 — intervention group
Group type: COMPARATOR
Intervention: Client without explicitly elevated suicide risk
Number of subjects: 86
Study 28128852 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg GLE + 80 mg PIB (arm A)
Number of subjects: 50
Study 28128852 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg GLE + 120 mg PIB with 800 mg once-daily RBV (arm B)
Number of subjects: 50
Study 28128852 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg GLE + 120 mg PIB without RBV (arm C)
Number of subjects: 50
Study 26050074 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-start cueing exercise program
Number of subjects: 21
Study 26050074 — intervention group
Group type: COMPARATOR
Intervention: Delayed-start cueing exercise program
Number of subjects: 21
Study 22093001 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh-frozen allogeneic (AL) block bone grafts
Number of subjects: 26
Study 22093001 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous (AT) block bone grafts
Number of subjects: 26
Study 21733435 — intervention group
Group type: EXPERIMENTAL
Intervention: Augment™ Bone Graft
Number of subjects: 20
Study 21733435 — intervention group
Group type: COMPARATOR
Intervention: ABG
Number of subjects: 20
Study 21733435 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 19955857 — intervention group
Group type: EXPERIMENTAL
Intervention: LAT patients
Number of subjects: 226
Study 19955857 — intervention group
Group type: EXPERIMENTAL
Intervention: LAT patients without warfarin
Number of subjects: 226
Study 19955857 — intervention group
Group type: EXPERIMENTAL
Intervention: LAT patients with INR >= 2.0
Number of subjects: 226
Study 19955857 — intervention group
Group type: EXPERIMENTAL
Intervention: LAT patients undergoing repeat TEE
Number of subjects: 226